Evidence map›Paper›PMID 40213558›Full record

ArticleFrontiers in immunology2025

Screening and mechanistic study of natural compounds that enhance T cell anti-tumor effects post-heat treatment.

Zhaoyi Wang, Zhongqi Diao, Yiyan Zhang, Jiangying Liu, Yeshan Li, Zijin Sun, Huimin Zhen, Haojia Wang, Siyun Yang, Tieshan Wang and 1 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhaoyi WangSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Zhongqi DiaoDepartment of Cancer Research Institute, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, China.
Yiyan ZhangSchool of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
Jiangying LiuSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Yeshan LiSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Zijin SunSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Huimin ZhenBeijing Research Institute of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Haojia WangSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Siyun YangSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Tieshan WangBeijing Research Institute of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Lei NiSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Following the approval of Chimeric Antigen Receptor T-cell Immunotherapy(CAR-T) in multiple countries, the Food and Drug Administration (FDA) approved tumor-infiltrating lymphocytes (TILs) and T-cell receptor-engineered T cells (TCR-T) treatments this year. The utilization of adoptive immunotherapy in tumor treatment has become increasingly prominent. Optimizing the cytotoxic effects of immune cells under Methods: In the current experiment, we conducted Results and Discussion: The findings indicated that heating treatment augmented the cytotoxic effect of Jurkat cells against malignant tumors, and the optimal effect was achieved when T cells were exposed to 39°C for a duration of 24 hours(48% increase in cell proliferation rate compared to 37°C treatment). By triggering the generation of heat shock proteins and facilitating mitochondrial energy supply, the 39°C treatment amplified the anti-tumor functions of T cells. By analyzing the data, we identified 3 injectable solutions and more than 20 effective monomers capable of further enhancing the tumor-killing ability of T cells. High-throughput transcriptomics studies disclosed that the combination of thermotherapy and TCM promoted Jurkat cell proliferation, activation, and cytotoxic functions of Jurkat cells, thereby activating the Regulation of mitotic cell cycle to exert anti-tumor effects. The integration of transcriptomic and proteomic data demonstrated that Shengmai Injection significantly enhances the tumor-killing effect of Jurkat cells by down-regulating the Regulation of Apoptosis and Regulation of mitotic cell cycle signaling pathways.

Indexed as

Biological ProductsHot TemperatureImmunotherapy, AdoptiveNeoplasmsT-LymphocytesApoptosisCoculture TechniquesHumansJurkat CellsK562 CellsBiological Productsadoptive cell therapyChinese medicineenhance immunityproteomicsRNA-Seqtemperatureuntargeted metabolomics

Identifiers

PMID40213558
PMCPMC11983556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.